	US 11,992,504 B2
	Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
John H. Lee, San Diego, CA (US); Laurent H. Boissel, San Diego, CA (US); and Hans G. Klingemann, San Diego, CA (US)
Assigned to ImmunityBio, Inc., Culver City, CA (US)
Filed by ImmunityBio, Inc., Culver City, CA (US)
Filed on Nov. 20, 2020, as Appl. No. 16/953,879.
Claims priority of provisional application 62/938,201, filed on Nov. 20, 2019.
Prior Publication US 2021/0145879 A1, May 20, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); C07K 14/735 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01)

CPC A61K 35/17 (2013.01) [C07K 14/70535 (2013.01); C07K 16/2827 (2013.01); C12N 5/0646 (2013.01)]

11 Claims

1. A recombinant natural killer (NK)-92 cell transfected with a plasmid expression vector and gamma (γ)-irradiated,

wherein the plasmid expression vector comprises a nucleic acid that encodes i) a homing receptor; ii) an antigen binding protein (ABP) or a chimeric antigen receptor (CAR) that specifically binds a target antigen; iii) an Fc Receptor; and iv) a secreted immune modulator, wherein the secreted immune modulator is a TGFβ inhibitor,

wherein the homing receptor is selected from the group consisting of a G protein-coupled receptor, a chemokine receptor, a cytokine receptor, a cell adhesion molecule, a selectin, and an integrin,

wherein the TGFβ inhibitor has the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:66 and

wherein the nucleic acid is operably linked to a promoter.